You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Implementing Evidence-Based Recommendations for the Management of NASH

  • Authors: Quentin M. Anstee, BSC (Hons), MD, BS, PhD, MRCP (UK), FRCP; Manal F. Abdelmalek, MD, MPH; Zobair M Younossi, MD, MPH
  • CME / ABIM MOC Released: 9/12/2022
  • Valid for credit through: 9/12/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for gastroenterologists, diabetologists and endocrinologists, primary care physicians, and anyone who manages patients at risk for nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH).

The goal of this activity is that learners will be better able to diagnose and manage patients with NAFLD/NASH.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of noninvasive tests in assessing/monitoring patients with NAFLD/NASH
    • Evidence-based treatment recommendations based on risk for liver fibrosis
  • Have greater competence related to
    • Using evidence-based testing to risk-stratify patients with NAFLD/NASH


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


  • Quentin M. Anstee, BSC (Hons), MD, BS, PhD, MRCP (UK), FRCP

    Professor of Experimental Hepatology
    and Honorary Consultant Hepatologist
    Translational and Clinical Research
    Institute Faculty of Medical Sciences
    Newcastle University
    Newcastle Upon Tyne, United Kingdom


    Quentin M. Anstee, BSC (Hons), MD, BS, PhD, MRCP (UK), FRCP, has the following relevant financial relationships:
    Consultant or advisor for: 89Bio; Allergan Akero; Altimentiv Altimmune; AstraZeneca; Axcella; Bristol Myers Squibb; CymaBay; Eli Lilly & Company Ltd.; Galmed; Genentech; HistoIndex; Indalo; Intercept Pharma Europe Ltd.; Inventiva; IQVIA; Janssen; Johnson & Johnson; Madrigal; MedImmune; Medpace; Merck; Metacrine; NGMBio; North Sea Therapeutics; Novartis; Novo Nordisk A/S; PathAI; Pfizer Ltd.; Poxel; ProSciento; Roche; Servier; ProSciento; Roche; Servier; Shionogi; Terns
    Speaker or member of speakers bureau for: Abbott Laboratories; Allergan/Tobira; Bristol Myers Squibb; Clinical Care Options; Falk; Fishawack; Genfit; Gilead; Integritas Communications; Kenes
    Research funding from: Allergan/Tobira; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Glympse Bio; Intercept; Novartis Pharma AG; Pfizer Ltd.
    Other: Coordinator of the EU IMI-2 LITMUS consortium, which is funded by the EU Horizon 2020 programme and EFPIA

  • Manal F. Abdelmalek, MD, MPH

    Professor of Medicine
    Mayo Clinic
    Rochester, Minnesota, United States


    Manal F. Abdelmalek, MD, MPH, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb; Hanmi; Inventiva; Madrigal; NGM Bio; Novo Nordisk; SonicIncytes; Theratherapeutics
    Research funding from: Allergan; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Durect; Enanta; Enyo; Galactin; Galmed; Genentech; Genfit; Gilead; Hanmi; Intercept; Inventiva; Madrigal; NGM Bio; Novo Nordisk; Poxel; TARGET Pharmaceuticals; Viking

  • Zobair M. Younossi, MD, MPH

    President, Inova Medicine Services
    Professor and Chairman
    Department of Medicine, Inova Fairfax Medical Campus
    Falls Church, Virginia, United States


    Zobair M. Younossi, MD, MPH, has no relevant financial relationships.


  • Briana Betz, PhD

    Medical Education Director, Medscape, LLC


    Briana Betz, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Implementing Evidence-Based Recommendations for the Management of NASH

Authors: Quentin M. Anstee, BSC (Hons), MD, BS, PhD, MRCP (UK), FRCP; Manal F. Abdelmalek, MD, MPH; Zobair M Younossi, MD, MPHFaculty and Disclosures

CME / ABIM MOC Released: 9/12/2022

Valid for credit through: 9/12/2023


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print